PMID: 6411052Jul 1, 1983Paper

Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin

Arteriosclerosis : an Official Journal of the American Heart Association, Inc
G H RaoJ G White

Abstract

Previous investigations have shown that ibuprofen inhibits the second wave of platelet aggregation and blocks the conversion of 14C-arachidonic acid to thromboxane. However, the influence of the drug on platelet function and cyclooxygenase is transitory, lasting only 24 hours. The present study has taken advantage of the short-lived influence of ibuprofen to study its interaction with the long-term effects of aspirin. As expected, both aspirin and ibuprofen suppressed platelet cyclooxygenase activity and function, but addition of aspirin to ibuprofen-treated platelets did not increase the degree of inhibition in vitro. Platelet function and prostaglandin synthesis recovered completely 26 hours following ingestion of ibuprofen, but remained compromised 26 hours after taking aspirin. When 650 mg of aspirin was administered after ibuprofen, platelet function and cyclooxygenase activity recovered as completely at 26 hours as did platelets which had been exposed to ibuprofen alone. Thus, prior exposure to ibuprofen in vivo completely protected cyclooxygenase from the irreversible effects of aspirin. Our findings indicate that ibuprofen-like indomethacin and other nonsteroidal antiinflammatory drugs react with the heme group of cyclo...Continue Reading

References

Feb 1, 1979·Prostaglandins and Medicine·D A PetersonJ G White
Feb 1, 1978·The Journal of Clinical Investigation·J W BurchP W Majerus
Dec 1, 1977·The Keio Journal of Medicine·Y Ikeda
Nov 1, 1978·Clinical Pharmacology and Therapeutics·B A McIntyreM J Inwood
Aug 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·G J RothP W Majerus
Dec 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·L H Rome, W E Lands
Sep 1, 1975·The Journal of Clinical Investigation·G J Roth, P W Majerus
Jun 23, 1971·Nature: New Biology·J B Smith, A L Willis
Apr 1, 1969·Proceedings of the Society for Experimental Biology and Medicine·E M Glenn, B J Bowman
Apr 13, 1982·Biochimica Et Biophysica Acta·G H RaoJ G White
Apr 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·J L HumesF A Kuehl
Jul 1, 1982·Prostaglandins, Leukotrienes, and Medicine·G H RaoJ G White
Feb 1, 1981·Thrombosis Research·E E Nishizawa, D J Wynalda

❮ Previous
Next ❯

Citations

Mar 1, 1984·Prostaglandins, Leukotrienes, and Medicine·G H RaoJ G White
Apr 1, 1985·Prostaglandins, Leukotrienes, and Medicine·G H Rao, J G White
Mar 1, 1987·Prostaglandins, Leukotrienes, and Medicine·G H RaoJ G White
Jul 11, 2002·European Journal of Pharmacology·Rainer Amann, Bernhard A Peskar
Apr 12, 2003·Trends in Neurosciences·Ashley I Bush
Sep 15, 1998·Trends in Neurosciences·C I De ZeeuwT J Ruigrok
Dec 10, 2002·Neurobiology of Aging·Ashley I Bush
Apr 9, 2009·Nature Reviews. Cardiology·Joseph M SweenyValentin Fuster
Jun 6, 2002·British Journal of Clinical Pharmacology·D J W van KraaijE J Vollaard
Dec 26, 2001·The New England Journal of Medicine·F Catella-LawsonG A FitzGerald
Sep 2, 2008·Journal of Translational Medicine·Kenneth A SchwartzAnthony C De Franco
Nov 22, 2001·Proceedings of the National Academy of Sciences of the United States of America·M OuelletM D Percival
Aug 10, 2012·Platelets·Marie Lordkipanidzé
Aug 29, 2007·Journal of Thrombosis and Haemostasis : JTH·G de Gaetano, C Cerletti
Apr 14, 2006·Basic & Clinical Pharmacology & Toxicology·Thomas M MacDonald, Li Wei
May 9, 2013·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Nicole Dodge ZantekAlan T Hirsch
Dec 6, 2017·Postgraduate Medicine·Chris Walker, Luigi M Biasucci
Jun 17, 2004·Journal of Clinical Pharmacology·Joanne Van RynMichel Pairet
Jul 2, 2011·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Naoko ItoYasuhiko Yamada
Oct 16, 2004·Fundamental & Clinical Pharmacology·Anwar UmarNicholas Moore
May 5, 2005·The Annals of Pharmacotherapy·Shelby L CormanNicole T Ansani
Nov 16, 2010·Journal of Internal Medicine·I S MackenzieL Wei
Feb 20, 2015·Anesthesia and Analgesia·Neal Stuart GersteinPeter M Schulman
Aug 28, 2003·Journal of Thrombosis and Haemostasis : JTH·G De Gaetano, C Cerletti
Mar 9, 2013·Expert Review of Cardiovascular Therapy·Bianca RoccaFrancesca Pagliaccia
Jan 29, 2020·Research and Practice in Thrombosis and Haemostasis·Ben DriverDianne E van der Wal
Jan 10, 2020·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Nicholas Moore
Apr 11, 2008·Congestive Heart Failure·Debabrata Mukherjee
May 26, 2018·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Mai DuongNicholas Moore
Nov 28, 2018·Thérapie·Nicholas MooreCecile Droz
Feb 15, 2001·The American Journal of Medicine·F Catella-Lawson, L J Crofford
Mar 29, 2008·American Heart Journal·Patrick GladdingHarvey White

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.